Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Operating Leases (2019 - 2025)

Pulmonx has reported Operating Leases over the past 7 years, most recently at $18.1 million for Q4 2025.

  • Quarterly Operating Leases fell 2.46% to $18.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.1 million through Dec 2025, down 2.46% year-over-year, with the annual reading at $18.1 million for FY2025, 2.46% down from the prior year.
  • Operating Leases was $18.1 million for Q4 2025 at Pulmonx, down from $19.4 million in the prior quarter.
  • Over five years, Operating Leases peaked at $19.4 million in Q3 2025 and troughed at $1.1 million in Q4 2023.
  • The 5-year median for Operating Leases is $7.5 million (2021), against an average of $10.0 million.
  • Year-over-year, Operating Leases plummeted 71.27% in 2023 and then surged 1574.05% in 2024.
  • A 5-year view of Operating Leases shows it stood at $6.8 million in 2021, then tumbled by 43.76% to $3.8 million in 2022, then plummeted by 71.27% to $1.1 million in 2023, then surged by 1574.05% to $18.5 million in 2024, then decreased by 2.46% to $18.1 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Operating Leases are $18.1 million (Q4 2025), $19.4 million (Q3 2025), and $18.6 million (Q2 2025).